constructs the flow, precipitation and application of full-link data in the clinical trial stage.
This article is an original IPO Early Know
Author｜Stone Jin
According to IPO Early Know, Shanghai Yaocheng Health Technology Co., Ltd. (hereinafter referred to as "Yaocheng") recently completed tens of millions of US dollars in A+ round financing. The lead investor in this round is Hankang Capital (Yaocheng original seed round and A round investor), the follower is Boston Investment (B Capital), and Huaxing Capital serves as the exclusive financial advisor for this round of financing.
Yaocheng Health Technology was officially established in early August 2020 and its headquarters is located in Shanghai, China. focuses on using computer technology to realize the informatization and intelligence of all scenarios and full links of clinical research in life sciences, helping the life science industry to reduce costs and increase efficiency in the innovation and research and development stage. The members of the Yaocheng team mainly come from companies in related fields such as Google, Verily, Splunk, Medidata, Veeva, Wuzhou AppTec , etc.
In May 2021, Yaocheng launched the AuroraPrime 1.0 system, a new generation clinical research cloud platform designed for tomorrow, and completed a round of RMB A financing of RMB 100 million in July of the same year; in May 2022, the AuroraPrime 2.0 system was released online, realizing the full-link integration and informatization of trials that began with the writing of clinical research plans, and officially announced the product strategy , which fully embraced the direction of remote intelligent clinical research (DCT); in August 2022, Yaocheng officially settled in Shanghai SK Building, a landmark building in Houtan, Pudong, Shanghai. Chen Xiao, CEO of
Yaocheng Health Technology, said: "Yaocheng is a technology-based startup company. Our product and technology research and development team mainly comes from a group of world-leading high-tech companies. Since its inception in 2020, we have focused on exploring more possibilities for innovation-enabled computer science in the field of clinical research in life sciences. From the true integrated implementation of the underlying architecture of the system to the innovative and intelligent application of multiple professional deep scenarios, theYaocheng team has fulfilled our commitment to customers and investors very firmly. Based on our in-depth understanding of different scenarios in the field of clinical research, theYaocheng AuroraPrime clinical research platform starts with solution writing as the starting point, and the Clinical Logic Engine (Clinical Logic) Engine) has built the circulation, precipitation and application of full-link data in the clinical trial stage. With the world's leading technical capabilities and product design concepts, we are bringing users a different tomorrow of informatization and intelligence in clinical research. "Zhang Zhi, chief commercial officer of
yaocheng Health Technology, said: "Yaocheng is very concerned about the success of customers. We deeply understand the needs of the industry and continue to explore future trends to achieve the users' truly ideal system experience and application value. Our product R&D team has forward-looking design concepts and creative implementation capabilities, so that Yaocheng's products can be widely recognized by industry experts as soon as they are released. From traditional EDC and RTSM systems, to Yaocheng's innovative intelligent solution writing system, to remote intelligent clinical research systems, and more future-oriented data-driven The dynamic intelligent clinical system, Yaocheng has carried out in-depth cooperation with many leading companies in the field of life science innovation at home and abroad. "Hankang Capital Management Partner Yuan Quanhong said: "Hankang Capital has always focused on providing support to outstanding innovative companies in the life science industry and accompanying them to success. In the process of medical innovation, the importance of clinical research is unquestionable. While ensuring compliance, enterprises should make full use of information technology to improve the data flow and application efficiency of clinical trials and accelerate the launch of innovative drugs . Yaocheng is such an innovative enterprise that is leading the development trend of clinical trial informationization and has leading technologies."
Boston Investment (B Cai Wei, managing partner and head of China, said: " is a product that is required by regulatory requirements, and the market space for clinical trial software is broad.Under the current industry trend of decentralization and platform integration of clinical trials, powerful innovative companies have sufficient opportunities to enter the fast lane of growth . The Boston investment team has been paying attention to the medical and healthcare and corporate services track for a long time. We highly recognize Yaocheng's top product capabilities and innovation capabilities demonstrated in this cross-section. We are very happy to see that Yaocheng has been continuously enriching its product line since its establishment two years ago, achieving rapid order growth, and has been recognized and selected by many top pharmaceutical companies in the industry. Boston Investment expects to continue to cooperate in depth with Yaocheng in the future and provide empowerment in various aspects such as international development. "
Xie Yijing, managing director of Huaxing Capital and head of the Medical and Life Science Technology Group, said: "We are honored to assist Yaocheng Health Technology in completing this round of financing transactions. The Yaocheng Health Technology team, which has cross-border integration of , has a deep understanding of the clinical research needs in the field of life sciences, looks at the world based on local areas and makes a forward-looking strategic layout, and has a strong technology and execution ability to deploy the integrated and intelligent platform of clinical digitalization of life sciences in a short time, and accelerates the digitalization process of clinical research in the field of life sciences . We believe that Yaocheng Health Technology will accelerate its development with the continuous support of new and old shareholders, and continue to empower the field of life sciences to enter a new era of digitalization and intelligence. ”
